Paul Statkevich
153 works · 6,881 citations · h-index 40
Top works
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
- Ezetimibe
- Phase I study of temozolomide in paediatric patients with advanced cancer
- Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
- Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
- Treating cancer with PEG Intron
- Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
- Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome
- Disposition of the Selective Cholesterol Absorption Inhibitor Ezetimibe in Healthy Male Subjects
- High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma
- A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe
- Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies
- Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
- Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease
- A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
- Ezetimibe does not affect the pharmacokinetics of oral contraceptives
- Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors
- High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma
- A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.